



**SABINE NDZENGUE AMOA**

# **Health for all and patents on medicines: The major drift**

 **NAS**  
ÉDITIONS



COLLECTION  
**POING LEVÉ**





**SABINE NDZENGUE AMOA**

**HEALTH FOR ALL AND PATENTS ON  
MEDICINES: THE MAJOR RIFT**

HEALTH FOR ALL AND PATENTS ON  
MEDICINES: THE MAJOR RIFT



## **SABINE NDZENGUE AMOA**

Health for all and patents on medicines: the major rift

*Cet ouvrage a été réalisé par : NAS ÉDITIONS*

*09, rue de la grand'maison, 77154, Villeneuve les  
bordes, France.*

*Téléphone/ phone number : 0033769845780*

*[Contact@naseditions.com](mailto:Contact@naseditions.com)*

*[www.naseditions.com](http://www.naseditions.com)*

*ISBN : 978-2-487682-27-6*

*EAN : 9782487682276*

*Dépôt légal, Juin /June 2024*

*[©](#)NAS ÉDITIONS, Juin /June 2024.*

*La première édition (en français) a été publiée par les  
éditions l'Harmattan en 2023. (© Editions l'Harmattan,  
2023).*



Le code de la propriété intellectuelle interdit les copies ou reproductions destinées à une utilisation collective.

Toute représentation ou reproduction intégrale ou partielle faite par quelque procédé que ce soit, sans le consentement de l'auteur ou de ses ayants droit ou ayants cause, est illicite et constitue une contrefaçon, aux termes des articles L. 335-2 et suivants du Code de la propriété intellectuelle.

\*\*\*The French intellectual property code prohibits copies or reproductions intended for collective use. Any representation or reproduction in whole or in part made by any means whatsoever, without the consent of the author or successors in title, is unlawful and constitutes an infringement, under the terms of articles L. 335-2 et seq. Intellectual property code.

## **ACRONYMS AND ABBREVIATIONS**

TRIPS	Trade-Related Aspects of Intellectual Property Rights
MA	Marketing authorization
ANDA	Abbreviated new drug application
SPC	Supplementary protection certificate
ECHP	Economic Committee for Health Products
WTO	World Health Organization
PUF	Presses universitaires de France
TEC	Treaty of European Communities
TFEU	Treaty on the functioning of the European Union.
RMCUE	Revue du marché commun et de l'Union européenne

WIPO

World international  
property organization

## INTRODUCTION

The gap between health for all and the imperative of profitability of patents on medicines is enormous.

In day-to-day operations, the decisive question of knowing the best choice between Health for all or profitability of intellectual property linked to patents in the pharmaceutical industry is a very tricky question.

The answer to this question is far from unanimous. It varies according to various paradigms; the variables change depending on the group to which one belongs (pharmaceutical companies; State; average citizen; philanthropist, etc.).

The global health crisis linked to the Covid 19 epidemic has highlighted the fight between health for all and the issue of intellectual property linked to patents in the pharmaceutical industry.

The WTO decision of June 17, 2022, cast a chill in the pharmaceutical sector.

The authorization granted to developing States to be able to lift patents linked to Covid vaccines for five years has not only made people happy.

Continuing discussions on the extension of the TRIPS Decision to treatments and diagnostic tools will not help matters between the different opposing camps.

The inequalities in access to vaccines between the countries of the North and those of the South have reinforced the « capital importance » of the patent in the current era. The health of individuals and the imperative of profitability of patents are not always compatible.

However, the aim of medicine is to ensure and preserve the health of individuals both preventatively and curatively. Article L 5111-1 of the French Public Health Code sees it as: « any substance or composition presented as having curative or preventive properties with regard to human or animal diseases, as well as any substance or composition that can be used in humans or animals or which can be administered to them, with a view to establishing a medical diagnosis or restoring, correcting or modifying their physiological functions by exerting a pharmacological, immunological or metabolic action ».

In the pharmaceutical sector, the expiration of the patent, this industrial property title whose purpose is the protection of inventions and medicines; brings out various strategies on the part of firms.

When drug patents expire, generics invade the market. They bode well for the taxpayer and for social security. From now on, drug prices are very attractive. However, this does not come without corollaries for firms holding patents on original products. The drug research and development cycle are a long, complex, and very expensive process. The stages of development of this health product are generally: exploratory research, preclinical tests, and clinical research<sup>1</sup>.

These stages are specifically characterized by:

- ❖ Production of the selected molecule (active ingredient) in satisfactory quantity, respecting a certain number of quality and purity criteria.
- ❖ Then: testing the drug candidate, to evaluate its effectiveness and adverse effects (preclinical studies). This involves studying the fate of the drug in the body and its interactions with the body, in

---

1-Pouteau Laureline, *Evolution des stratégies Marketing des laboratoires pharmaceutiques face à l'émergence des génériques sur le marché de ville en France* ; Université de Paris 11, Faculté de Pharmacie de Chatenay Malabry, 2010, p 13.

particular its effectiveness (pharmacology) and its possible toxicity (toxicology).

- ❖ Subsequently, it is a question of making the molecule administrable in a suitable form (capsule, tablet, solution for injection, patch, syrup, suppository, cream, etc.) by combining the active ingredient with excipients.
- ❖ Then, it is appropriate to continue to monitor adverse effects and seek to optimize the doses that will be administered in the first clinical studies.
- ❖ Finally, if the preclinical stages are satisfactory, the drug will be tested on humans, as part of clinical trials.

**This last step: the human testing phase takes place in four phases:**

<u>INTRODUCTION</u> .....	9
<u>I- The patent on the medicine: « an intellectual property with an imperative of profitability »</u> .....	17
<u>A- The patent criteria</u> .....	17
<u>B- Evolution of the legislative framework for patents...</u>	18
<u>□ The establishment of patent law in France dates back to 1791.</u> .....	18
<u>□ The Agreement on Trade-Applicable Aspects of Intellectual Property Rights (TRIPS)</u> .....	19
<u>C- Saga on patents around the world – « the imperative of profitability » against « patient rights »</u> .....	21
<u>1- The victories of « patients’ rights » over « patent law »</u> .....	22
<u>South Africa - antiretroviral drugs</u> .....	22
<u>India -Anti-cancer drug Glivec</u> .....	25
<u>2- Defeats: The victories of « patent law » over « patients’ rights »</u> .....	26
<u>France-Anti-Hepatitis C drug- Sovaldi</u> .....	26



<u>France-Anti-Hepatitis C drug- Sovaldi .....</u>	26
<u>3- Other alternatives : compromises .....</u>	29
<u>□ Brazil- Off-patent medicines.....</u>	29
<u>□ Pharmaceutical companies-Donations, price reduction.....</u>	30
<u>Covid 19- lifting of patents on vaccines for 5 years and continued discussions on the extension of the TRIPS Decision to treatments and diagnostic tools.....</u>	31
<u>II- The supervision of « courteous » strategies by the legislator: the French example.....</u>	35
<u>A- Granting of marketing authorization before expiration of intellectual property rights.....</u>	36
<u>B- Controversies relating to the contributions of these strategies to consumer health.....</u>	39
<u>1- The perverse effects of capitalization on the brand... </u>	40
<u>2- The likely side effects of moving the drug to the OTC market .....</u>	45
<u>III- Sanctions for « anti-competitive » strategies by the French competition authority.....</u>	47

<u>A- Legislative framework through intellectual property and trade codes and the Treaty on the Functioning of the European Union (TFEU)</u> .....	48
<u>1- Protection of patents by the intellectual property code</u> .....	48
<u>2 - Explicit prohibitions of strategies by the commercial code and the TFEU</u> .....	49
<u>(i)</u> .....	50
<u>(ii) The prohibitions of the TFEU and the regulations of the European Commission and Council</u> .....	51
<u>B- Sanctions for prohibited practices</u> .....	55
<u>1- The practice of denigration between injunctions and fines</u> .....	56
<u>2- The influence on the legal duration of protection of the drug between legalization and absence of legislation</u> ....	61
<u>(i) Additional patent filings</u> .....	61
<u>(ii) Requests for extension certificates</u> .....	62
<u>(iii) The use of data exclusivity</u> .....	63

<u>3- Harsh financial penalties in the face of entry deferral agreements</u> .....	64
<u>4- Abuse of dominant position by agreement on prices between acceptance on merit and financial sanctions</u> ....	67
<u>CONCLUSION</u> .....	71
<u>Table des matières</u> .....	78







## **Health for all and patents on medicines: The major rift**

The gap between health for all and the imperative of profitability of patents on medicines is enormous.

This work highlights the eternal conflict between health for all and the imperative of profitability of intellectual property linked to patents on medicines in the pharmaceutical industry. Health for all is difficult to reconcile with the need for patent profitability. Obtaining a patent for a drug rhymes with an obligation of profitability. The expiration of the patent on the drug generates strategies on the part of pharmaceutical companies that are not in the service of health. Does health have a price?

**Sabine Ndzengue Amoa** is a legal consultant, trainer, speaker specializing in health law, environmental law, public law.

14 euros



9 782487 682276